Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-12-19
1999-03-23
Cook, Rebecca
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514460, 560 8, 560129, 562498, A61K 3153, A61K 3135, C07C 6976, C07C 6112
Patent
active
058859926
DESCRIPTION:
BRIEF SUMMARY
This is 371 of PCT/JP95/01249 filed Jun. 22, 1995.
TECHNICAL FIELD
The present invention relates to a hederagenin derivative, its pharmacologically acceptable salt, and a solvate of either of said derivative and salt, which are of value as medicines.
The compounds according to the present invention have inhibitory activity of mesangial cell proliferation and are useful for the treatment of nephritis.
BACKGROUND TECHNOLOGY
According to the site of principal lesions, nephritis is classified into glomerulonephritis, interstitial nephritis and pyelonephritis, for instance. The most representative of all is glomerulonephritis in which the glomerular tuft is the affected site. Today, nephritis is synonymous with glomerulonephritis (Medical Dictionary, 1st ed., 570, 1987).
Histopathological findings which are most frequently obtained in human glomerulonephritis and considered to be of prognostic importance are mesangial cell proliferation and hyperplasia of the matrix produced by mesangial cells (hereinafter referred to as mesangial matrix). These findings are noted in nearly all types of proliferative glomerulonephritis, inclusive of IgA nephropathy, membranous proliferative glomerulonephritis, and lupus nephritis, in common (Iida: Kindney and Dialysis, 35, 505-509, 1993). And as the mesangial cell proliferation and associated production of mesangial matrix progress, the glomeruli fall into a terminal stage, so call glomerulosclerosis. Therefore, any compound that inhibits mesangial cell proliferation and production of mesangial matrix is of great value as a therapeutic agent for glomerulonephritis.
Two processes are known for mesangial cell proliferation in glomerulonephritis. In the first process, the complement, platelets, and infiltrating cells are involved. Thus, deposition of the immune complexes produced by immunological mechanisms on the glomeruli takes place in situ and activation of the complement and platelets and infiltration of macrophages and neutrophils then occur. These cells release a variety of growth factors and cytokines to activate the mesangial cells and stimulate their proliferation. The second process is a process wish which mesangial cells themselves are associated. Thus, it is a process in which activated mesangial cells themselves release a variety of growth factors and cytokines and the cells releasing them and the adjacent mesangial cells become activated or proliferate. Thus, mesangial cells are activated and proliferate through a complex system consisting of a plurality of processes.
Therefore, when the treatment of glomerulonephritis is considered, it is inconceivable that the mesangial cell proliferation can be sufficiently inhibited even if a given stage in first process mentioned above, for example the stage mediated by the complement and platelets, is inhibited. In fact, it is reported that administration of an antiplatelet drug alone is therapeutically little effective for human nephritis in active stage (Dohi et al., Clinics All-round, 38, 865-870, 1989).
It is known that, among natural substances of the plant origin, there exist compounds having antinephritic activity. For example, the usefulness of pentacyclic triterpene derivatives in the treatment of nephritis and other diseases is indicated in Japanese Laid-Open S61-37749 (an oleanene derivative), Japanese Laid-Open S61-85344 (an oleanene derivative), Japanese Laid-Open H2-73012 (a bryonolic acid derivative), Japanese Laid-Open H4-290846 (a bryonolic acid derivative), and Japanese Laid-Open S61-43141 (a lupane derivative). However, there is no disclosure of an experimental example demonstrating the utility of such compounds in the treatment of nephritis, nor is there a suggestion that they ever have mesangial cell proliferation inhibitory activity.
Hederagenin (3.beta.,23-dihydroxyolean-12-en-28-oic acid) according to the present invention is a pentacyclic triterpene derivative available from natural sources such as Sapindus mukorossi, Hedera rhombea, Hedera helix, Fatsia japonica, etc. Hederagenin is known to hav
REFERENCES:
Chem. Pharm. Bull., 3340-3346(1982).
Studies on the Constituents of Clematis Species. V. On the Saponins of the Root of Clematis chinensis Osbeck, by Haruhisa Kizu and Tsuyoshi Tomimori.
Chem. Pharm. Bull., 1935-1939 (1972).
Seed Saponins of Akebia quinata Decne. I. Hederagenin 3-0-Glycosides, by Ryuichi Higuchi, Kazumoto Miyahara, and Toshio Kawasaki.
Indian Journal of Chemistry, vol. 29B, 425-429 (May 1990).
Cetyltrimethylammonium bromide catalysed sodium periodate oxidation of olean-12-en-28-ols and urs-12-en-28-ols: Construction of .increment..sup.11 -13.beta., 28-epoxy system of saikogenins: Partial synthesis of 16-deoxysaikogenin-F.dagger., by Rita Mehrotra, Chandan Singh and Satya Pal Popli.
Photochemistry, 615-621 (1984).
ENT-Labdane-Type Diterpene Glucosides form Leaves of Rubus Chingii, by Takashi Tanaka, Keiko Kawamura, Takumi Kitahara, Hiroshi Kohda and Osamu Tanaka.
Chem. Pharm. Bull., 2388-2393 (1979).
Studies on the Constituents of Clematis Species. I. On the Saponins of the Root of Clematis chinensis Osbeck, by Haruhisa Kizu and Tsuyoshi Tomimori.
Tetrahedron, vol. 49, No. 33, 7193-7214 (1993).
The Invention of Radical Reactions. XXXI. Diphenylsilane: A Reagent for Deoxygenation of Alcohols via Their Thiocarbonyl Derivatives, Deamination via Isonitriles, and Dehalogenation of Bromo- and Iodo-Compounds by Radical Chain Chemistry, by Derek H.R. Barton, Doo Ok Jang and Joseph Cs. Jaszberenyi.
Bulletin de la Societe Royale des Sciences de Liege, 245-252 (1973).
Contribution a L'etude Chimique des Saponines d'une Sapindaceee Africaine: Eriocoelum Microspermum Radlk. ex de Wild, by C. Delaude and M. Davreux.
J.C.S. Chem. Comm., 1136-1137 (1981).
The Synthesis and Properties of a Series of Strong but Hindered Organic Bases, by Derek H.R. Barton, John D. Elliott, and Stephen D. Gero.
Chem. Pharm. Bull 24(6), 1314-1323 (1976).
Pericarp Saponins of Akebia quinata Decne. II. Arjunolic and Norarjunolic Acids, and Their Glycosides, by Ryuichi Higuchi and Toshio Kawasaki, Chem. Pharm. Bull 24(6), 1976.
Chem. Pharm. Bull 24(5), 1021-1032 (1976).
Pericarp Saponins of Akebia quinata Decne. I. Glycosides of Hederagenin and Oleanolic Acid, by Ryuichi Higuchi and Toshio Kawasaki, Chem.
J. Chem. Soc., Chem. Commun., 939-941 (1983).
New and Improved Methods for the Radical Decarboxylation of Acids, by Derek H.R. Barton, David Crich, and William B. Motherwell.
Choi et al, Planta Medica, 53(1), 62-65 (1987).
Barton et al. J.C.S. Chem. Comm., 15 732-733 (1980).
Madhusudanan et al, Indian J. Chem., Sect. B., 223 370-373 (1983).
CA 122:205207, Zheng et al, Feb. 9, 1995.
CA 121:150765, Kreppel et al, 1994.
CA 124:278388, Morota et al, 1995.
CA 122:203207, Zheng et al, Feb. 9, 1995.
CA 120:263529, Tauleneek et al, 1994.
Reg. No 6055-17-0, none avail.
Kandori Kazuhisa
Ohgi Tadaaki
Yoshifusa Hiroto
Cook Rebecca
Nippon Shinyaku Company Limited
LandOfFree
Triterpene derivative and medicinal composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triterpene derivative and medicinal composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triterpene derivative and medicinal composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2125614